Chasing 'Holy Grail' STAT3 target, Houston startup refuels with $74M to zero in on liver cancer
Tvardi launched out of Houston with the promise of finally developing the right inhibitors for the Holy Grail target of STAT3 — under the guidance of serial entrepreneur Ron DePinho and his colleague David Tweardy, a leading expert in the field. Almost three years later, they say they have the proof of concept data to keep going.
It’s good enough for a $74 million Series B, a big jump from the $9 million they got in the last round and, CEO Imran Alibhai would add, a reflection of the rep his team has built.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.